Skip to content

Study · Non-randomized trial · n = 17 · 2004

8 results

Improvement of alveolar glutathione and lung function but not oxidative state in cystic fibrosis.

Griese M, Ramakers J, Krasselt A, Starosta V, Van Koningsbruggen S, Fischer R, Ratjen F, Müllinger B, Huber RM, Maier K, Rietschel E, Scheuch G

American journal of respiratory and critical care medicine15 Jan 2004Cited by 77 (Europe PMC)

PMID14726422 (opens in a new tab)DOI10.1164/rccm.200308-1104oc (opens in a new tab)PepBankPUB-14726422
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanNon-randomized trialPharmacokinetics

    In cystic fibrosis, lavage glutathione concentration increased three- to fourfold at 1 hour after inhalation.

    In plain wordsIn cystic fibrosis, lung lavage glutathione concentration increased three- to fourfold at 1 hour after inhalation.

    Peptide
    Glutathione
    Outcome
    IncreaseLavage glutathione concentration at one hour
    Study

    n = 17

    Outcome group
    Pharmacokinetics · Respiratory
    Studied dose
    300 or 450 mg thrice daily · inhalation · 14 daysAs given in this study (human).

    Measurements

    Lavage glutathione concentration fold increase
    3 to 4 fold
    1 hour postinhalation

    Source sentences

    Summary
    Glutathione concentration in lavage 1 hour postinhalation was increased three- to fourfold and was still almost doubled 12 hours postinhalation.
    2 context sentences
    Summary · context
    In 17 additional patients bronchoalveolar lavage fluid was assessed before and after 14 days of inhalation with thrice-daily doses of 300 or 450 mg of glutathione.
    Summary · context
    Here we evaluated the effects of glutathione aerosol on lower airway glutathione levels, lung function, and oxidative status.
  2. 02HumanNon-randomized trialPharmacokinetics

    In cystic fibrosis, lavage glutathione concentration remained almost doubled at 12 hours after inhalation.

    In plain wordsIn cystic fibrosis, lung lavage glutathione concentration remained almost doubled at 12 hours after inhalation.

    Peptide
    Glutathione
    Outcome
    IncreaseLavage glutathione concentration at twelve hours
    Study

    n = 17

    Outcome group
    Pharmacokinetics · Respiratory
    Studied dose
    300 or 450 mg thrice daily · inhalation · 14 daysAs given in this study (human).

    Source sentences

    Summary
    Glutathione concentration in lavage 1 hour postinhalation was increased three- to fourfold and was still almost doubled 12 hours postinhalation.
    2 context sentences
    Summary · context
    In 17 additional patients bronchoalveolar lavage fluid was assessed before and after 14 days of inhalation with thrice-daily doses of 300 or 450 mg of glutathione.
    Summary · context
    Here we evaluated the effects of glutathione aerosol on lower airway glutathione levels, lung function, and oxidative status.
  3. 03HumanNon-randomized trialSafety outcome

    In cystic fibrosis, FEV(1) transiently decreased after glutathione inhalation.

    In plain wordsIn cystic fibrosis, lung function transiently decreased after glutathione inhalation.

    Peptide
    Glutathione
    Outcome
    DecreaseTransient FEV1 decrease after inhalation
    Study

    n = 17

    Outcome group
    Adverse events · Respiratory
    Studied dose
    300 or 450 mg thrice daily · inhalation · 14 daysAs given in this study (human).

    Source sentences

    Summary
    FEV(1) transiently dropped after inhalation but increased compared with pretreatment values after 14 days (p < 0.001).
    2 context sentences
    Summary · context
    In 17 additional patients bronchoalveolar lavage fluid was assessed before and after 14 days of inhalation with thrice-daily doses of 300 or 450 mg of glutathione.
    Summary · context
    Here we evaluated the effects of glutathione aerosol on lower airway glutathione levels, lung function, and oxidative status.
  4. 04HumanNon-randomized trialEfficacy outcome

    In cystic fibrosis, FEV(1) increased compared with pretreatment values after 14 days of glutathione inhalation.

    In plain wordsIn cystic fibrosis, lung function increased compared with pretreatment values after 14 days of glutathione inhalation.

    Peptide
    Glutathione
    Outcome
    IncreaseFEV1 after treatment
    Study

    n = 17

    Outcome group
    Respiratory function · Respiratory
    Studied dose
    300 or 450 mg thrice daily · inhalation · 14 daysAs given in this study (human).

    Measurements

    P value for FEV1 after 14 days versus pretreatment
    < 0.001
    glutathione inhalation, after 14 days versus pretreatment

    Source sentences

    Summary
    FEV(1) transiently dropped after inhalation but increased compared with pretreatment values after 14 days (p < 0.001).
    2 context sentences
    Summary · context
    In 17 additional patients bronchoalveolar lavage fluid was assessed before and after 14 days of inhalation with thrice-daily doses of 300 or 450 mg of glutathione.
    Summary · context
    Here we evaluated the effects of glutathione aerosol on lower airway glutathione levels, lung function, and oxidative status.
  5. 05HumanNon-randomized trialMechanism

    In cystic fibrosis, lavage oxidized protein content did not change with glutathione inhalation.

    In plain wordsIn cystic fibrosis, oxidized proteins in lung lavage did not change with glutathione inhalation.

    Peptide
    Glutathione
    Outcome
    No significant changeLavage oxidized proteins
    Study

    n = 17

    Outcome group
    Oxidative stress · Respiratory
    Studied dose
    300 or 450 mg thrice daily · inhalation · 14 daysAs given in this study (human).

    Source sentences

    Summary
    This improvement was not related to the lavage content of oxidized proteins and lipids, which did not change with treatment.
    2 context sentences
    Summary · context
    In 17 additional patients bronchoalveolar lavage fluid was assessed before and after 14 days of inhalation with thrice-daily doses of 300 or 450 mg of glutathione.
    Summary · context
    Here we evaluated the effects of glutathione aerosol on lower airway glutathione levels, lung function, and oxidative status.
  6. 06HumanNon-randomized trialMechanism

    In cystic fibrosis, lavage oxidized lipid content did not change with glutathione inhalation.

    In plain wordsIn cystic fibrosis, oxidized lipids in lung lavage did not change with glutathione inhalation.

    Peptide
    Glutathione
    Outcome
    No significant changeLavage oxidized lipids
    Study

    n = 17

    Outcome group
    Oxidative stress · Respiratory
    Studied dose
    300 or 450 mg thrice daily · inhalation · 14 daysAs given in this study (human).

    Source sentences

    Summary
    This improvement was not related to the lavage content of oxidized proteins and lipids, which did not change with treatment.
    2 context sentences
    Summary · context
    In 17 additional patients bronchoalveolar lavage fluid was assessed before and after 14 days of inhalation with thrice-daily doses of 300 or 450 mg of glutathione.
    Summary · context
    Here we evaluated the effects of glutathione aerosol on lower airway glutathione levels, lung function, and oxidative status.
  7. 07HumanNon-randomized trialMechanism

    In cystic fibrosis, lung function improvement after glutathione inhalation was not linked to lavage oxidized protein and lipid content.

    In plain wordsIn cystic fibrosis, lung function improvement after glutathione inhalation was not linked to oxidized protein and lipid content in lung lavage.

    Peptide
    Glutathione
    Outcome
    No significant changeLung function improvement association with lavage oxidation
    Study

    n = 17

    Outcome group
    Oxidative stress · Respiratory
    Studied dose
    300 or 450 mg thrice daily · inhalation · 14 daysAs given in this study (human).

    Source sentences

    Summary
    This improvement was not related to the lavage content of oxidized proteins and lipids, which did not change with treatment.
    3 context sentences
    Summary · context
    FEV(1) transiently dropped after inhalation but increased compared with pretreatment values after 14 days (p < 0.001).
    Summary · context
    In 17 additional patients bronchoalveolar lavage fluid was assessed before and after 14 days of inhalation with thrice-daily doses of 300 or 450 mg of glutathione.
    Summary · context
    Here we evaluated the effects of glutathione aerosol on lower airway glutathione levels, lung function, and oxidative status.

Studies that did not test the peptide alone1

In this study, Glutathione was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Glutathione.

  1. 08HumanNot a test of Glutathione aloneNon-randomized trialPharmacokinetics

    In cystic fibrosis, intrathoracic aerosol deposition was 86.3 +/- 1.4% of the emitted dose using the studied inhalation device.

    In plain wordsIn cystic fibrosis, 86.3 +/- 1.4% of the emitted aerosol dose deposited inside the chest with the studied device.

    Peptide
    Glutathione
    Outcome
    Not applicableIntrathoracic aerosol deposition
    Study

    n = 6

    Outcome group
    Pharmacokinetics · Respiratory

    Measurements

    Intrathoracic deposition
    86.3%
    of emitted dose
    Intrathoracic deposition reported +/- uncertainty (type not stated)
    1.4%
    86.3 +/- 1.4% of the emitted dose

    Source sentences

    Summary
    Intrathoracic deposition was 86.3 +/- 1.4% of the emitted dose.
    2 context sentences
    Summary · context
    Pulmonary deposition of a radiolabeled monodisperse aerosol generated with a Pari LC Star nebulizer (Allergy Asthma Technology, Morton Grove, IL) connected to an AKITA inhalation device (Inamed, Gauting, Germany) was determined in six patients.
    Summary · context
    Here we evaluated the effects of glutathione aerosol on lower airway glutathione levels, lung function, and oxidative status.

    In this study, Glutathione was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Glutathione.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 3NCT01450267

Inhaled Glutathione (GSH) Versus Placebo in Cystic Fibrosis

Serafino A. Marsicon = 150Jun 2010 to est. Dec 2012

Cystic Fibrosis

Trial pageClinicalTrials.govUpdated 13 Oct 2011

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.